Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 2010-2016

  Siraj, Muhammad A ^a   Pichon, Christophe ^a   Radu, Aurelian ^b   Ghinea, Nicolae ^a  

^a PSL RESEARCH UNIVERSITY   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Blood vessels; FSHR; Immunohistochemistry; Kidney cancer; Sunitinib

Indexed keywords

ANGIOGENESIS INHIBITOR; FOLLITROPIN RECEPTOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB; TUMOR MARKER;

ARTICLE; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RECEPTORS, FSH; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84865438725     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01495.x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, et al Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Kontovinis LF, Papazisis KT, Touplikioti P, et al Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009; 9: 82. doi: 10.1186/1471-2407-9-82.
3. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011; 19: 617-23.
4. Mena AC, Pulido EG, Guillén-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010; 21: S3-11.
5. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumours. Clin Ther. 2007; 29: 1338-53.
6. Faivre S, Demetri G, Sargent W, et al Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6: 734-45.
7. Mendel DB, Laird AD, Xin X, et al In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-37.
8. O'Farrell AM, Abrams TJ, Yuen HA, et al SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101: 3597-605.
9. Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2010; 10: 305-17.
10. Motzer RJ, Michaelson MD, Redman BG, et al Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24.
11. Motzer RJ, Rini BI, Bukowski RM, et al Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 2516-24.
12. Motzer RJ, Hutson TE, Tomczak P, et al Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24.
13. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer. 2006; 42: 3127-39.
14. Bhojani N, Jeldres C, Patard JJ, et al Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008; 53: 917-30.
15. Tanji N, Yokoyama M. Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Clin Exp Nephrol. 2011; 15: 331-8.
16. Pirrotta MT, Bernardeschi P, Fiorentini G. Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem. 2011; 18: 1651-7.
17. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 2011; 16: 14-22.
18. Singer EA, Gupta GN, Srinivasan R. Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol. 2011; 23: 283-9.
19. Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer. 2009; 115: 2368-75.
20. Remák E, Charbonneau C, Négrier S, et al Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008; 26: 3995-4000.
21. Radu A, Pichon C, Camparo P, et al Expression of follicle-stimulating hormone receptor in tumour blood vessels. N Engl J Med. 2010; 363: 1621-30.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-47.
23. Vannier B, Loosfelt H, Meduri G, et al Anti-human FSH receptor monoclonal antibodies: immunochemical and immunocytochemical characterization of the receptor. Biochemistry. 1996; 35: 1358-66.
24. Porta C, Paglino C, De Amici M, et al Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010; 77: 809-15.
25. Paule B, Bastien L, Deslandes E, et al Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One. 2010; 5: e10715.
26. Welti JC, Gourlaouen M, Powles T, et al Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene. 2011; 30: 1183-93.
27. Raymond E, Dahan L, Raoul JL, et al Sunitinib malate for the treatment of pancreatic neuroendocrine tumours. N Engl J Med. 2011; 364: 501-13.
28. Huang D, Ding Y, Li Y, et al Sunitinib acts primarily on tumour endothelium rather than tumour cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010; 70: 1053-62.
29. Alam H, Weck J, Maizels E, et al Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone. Endocrinology. 2009; 150: 915-28.